Merz Aesthetics®Announces New Arms and Abdomen* Indication for Ultherapy PRIME, the Only Ultrasound Solution With Integrated Real-Time Visualization
5.11.2025 14:00:00 CET | Business Wire | Press release
Latest Intention for USE Expands to Improve the Appearance of Skin Laxity on the Posterior and Anterior Armsand Abdomen, to launch in the United States before worldwide expansion.
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the upcoming availability of UltherapyPRIMEto improve the appearance of skin laxity on the anterior arms and posterior arms, and abdomen.
Ultherapy PRIME is the only solution with integrated real-time visualization to treat the upper face, lower face, neck, décolleté, and now the body*.1 The new indications will launch in the United States before expanding to markets worldwide, with commercial rollout in EMEA planned for early 2026.** We are excited to share updates with our customers soon and look forward to supporting practices and patients with these innovative solutions.
“This indication expansion is proof of our incredible momentum, following last year’s successful Ultherapy PRIME launch,” said Bob Rhatigan, CEO, Merz Aesthetics. “By extending our reach from face*** to body*, we’re unlocking new treatment possibilities, meeting rising patient demand, and reinforcing our leadership in non-invasive skin lifting and tightening.”
Ultherapy PRIME builds on the legacy of Ultherapy®, which was recognized by a panel of experts as the Gold Standard in non-invasive skin lifting and tightening with over 3.5 million treatments performed§ globally and a 95% patient satisfaction rate.1-3 The skin lifting market is expanding rapidly and is expected to grow approximately 9% by 2030, driven largely by life stage (post-partum, menopause), and weight loss related skin laxity patient demographics.4
Ultherapy PRIME stimulates the body’s natural collagen and elastin production precisely where it’s needed. In just one session, Ultherapy PRIME lifts and tightens the upper face, lower face, neck, and décolleté. Now, Ultherapy PRIME also firms and tones the skin on the arms and abdomen - with no downtime and suitable for all skin tones1,5. It offers personalized, visible natural-looking results, along with younger looking skin, that can last up to a year or more on the face*** and 6 months or more on the arms and abdomen.4-7
“The Ultherapy PRIME platform offers all the signature benefits of Ultherapy for non-invasive skin lifting and tightening, plus the ability to improve skin laxity on the abdomen and arms in a single session,” said Dr. Sabrina Fabi, world-renowned Double Board-Certified Dermatologist and Dermatological Cosmetic Surgeon from San Diego, California. “This is of great value for my patients who want to keep the skin on their body looking as youthful as the skin on their face.”4,6,7
“These new indications for arms and abdomen* strengthen Ultherapy PRIME’s position as a multi-purpose skin lifting, tightening, and firming treatment solution,” said Alexis Stern, Chief Marketing Officer, Merz Aesthetics. “This exciting journey started a year ago when we launched Ultherapy PRIME as a platform to lift the face*** and with this next phase of growth for the platform we are now able to firm and tone the body.”*,1,6
To highlight the latest body* indications, Merz Aesthetics is also launching a new global campaign for Ultherapy PRIME. To learn more about Ultherapy PRIME, visit Ultherapy.com and follow @Ultherapy on Instagram.
About Merz Aesthetics
Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables and devices designed to meet each patient’s needs. Being family owned for more than 115 years; Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.
About Ultherapy:
The Ulthera System is intended to lift and sculpt the upper face, lower face, neck and décolleté, and to improve the appearance of skin laxity on the abdomen, anterior arms, and posterior arms. Reported adverse events from post marketing surveillance are available in the Instructions for Use (IFU). Please reference the IFU for additional information, including specific indications in your country, full product and safety information, and possible side effects.
The most common side effects reported in clinical trials were redness, swelling, pain and transient nerve effects. Talk to your practitioner for additional safety information and possible side effects.
*Indicated to improve the appearance of skin laxity on the abdomen, anterior arms and posterior arms.
**Timelines may vary by market based on regulatory approvals and will begin as soon as all required registrations are received.
***Face refers to the cleared indications for Ultherapy PRIME.
§Treatments performed with Ultherapy and Ultherapy PRIME.
References:
- Ulthera® Instructions for Use.
- Werschler WP, Werschler PS. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;9(2):27-33.
- Ultherapy PRIME Letter of Treatments Sold. Merz Aesthetics®, Herring L, Sr Director, Regulatory Affairs, Advertising and Promotion. July 16, 2025. Data on File.
- Data on File. Merz Custom Market Forecasting 2025.
- Marquardt K, Hartmann C, Wegener F, et al. Microfocused ultrasound with visualization induces remodeling of collagen and elastin within the skin. J Cosmet Dermatol. 2025;24(1):e16638. doi:10.1111/jocd.16638.
- Fabi SG, Joseph J, Sevi J, Green JB, Peterson JD. Optimizing patient outcomes by customizing treatment with microfocused ultrasound with visualization: gold standard consensus guidelines from an expert panel. J Drugs Dermatol. 2019;18(5):426-432.
- Park JY, et al. Customized Treatment Using Microfocused Ultrasound with Visualization for Optimized Patient Outcomes: A Review of Skin tightening Energy Technologies and a Pan-Asian Adaptation of the Expert Panel’s Gold Standard Consensus. J Clin Aesthet Dermatol. 2021;14(5): E70-E79.
- Sasaki G, Grossman J, Fabi SG, et al. Stimulation of Collagen Synthesis in Human Skin Following Microfocused Ultrasound Therapy. Presented at the ASDS 2018 Annual Meeting.
- Goldie K, Kerscher M, Fabi SG, Hirano C, Landau M, Lim TS, Woolery-Lloyd H, Mariwalla K, Park JY, Yutskovskaya Y. Skin Quality - A Holistic 360° View: Consensus Results. Clin Cosmet Investig Dermatol. 2021 Jun 14;14:643-654. doi: 10.2147/CCID.S309374. PMID: 34163203; PMCID: PMC8214518.
© 2025 Ulthera, Inc. All Rights Reserved. MERZ AESTHETICS is a trademark and/or registered trademark of Merz Pharma GmbH & Co. KGaA in the U.S. and/or certain other countries. ULTHERA, ULTHERAPY and ULTHERAPY PRIME are trademarks and/or registered trademarks of Ulthera, Inc. in the U.S. and/or certain other countries.
Various features of the ULTHERA® System are covered by U.S. patents identified at https://merzaesthetics.com/patents/. Other U.S. and international patents to which Ulthera, Inc. has rights are issued, published, or pending.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251105361450/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Manna Air Delivery Raises $50Million Series B as It Announces Plans to Expand in the United States1.4.2026 18:00:00 CEST | Press release
ARK Invest, backer of OpenAI, Anthropic, Tesla and SpaceX, the Ireland Strategic Investment Fund and Schooner Capital back new round bringing total funding to $110M Plans to scale to 40 bases in the United States, supported by seven years of operational orchestration experience, and recently expanded its global partnerships with Uber, joining Deliveroo, Just Eat and DoorDash in delivering everyday items by air. Manna Air Delivery, a global leader in consumer drone delivery, has announced a $50 million funding round to scale its proven operations further in the United States and Europe. The round brings Manna’s total funding to $110million. Manna now operates one of the most active consumer drone delivery networks in the world, with more than 250,000 regulated commercial UAV flights completed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310714366/en/ Manna Air Delivery raises $50m Series B Investors in the round include
Bureau Veritas Launches an Independent AI Assessment Offering for European Enterprises, Developed in Partnership with Amazon Web Services (AWS)1.4.2026 17:45:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces the launch of an AI systems audit to help European enterprises assess and demonstrate their compliance with the European Union's "AI Act" regulatory requirements. This offering combines on-site audits, document analysis, and direct testing to deliver an independent maturity report. Since the EU's AI regulation came into force in 2024, companies have faced major implementation challenges. According to a recent report*, 68% of them struggle to interpret the provisions of the text, while 60% have yet to put in place the governance needed to comply. Non-compliance can cost them up to 7% of annual revenue. Bureau Veritas has developed this new audit offering to help companies identify their compliance gaps and remedy them. Bureau Veritas's new audit offering comprises a pre-audit, document review, on-site audit, and direct testing, resulting in an independent report on the client's AI maturit
Greenland Resources Signs Eight Year Off-take Agreement With SSAB to Supply High Quality Molybdenum1.4.2026 16:29:00 CEST | Press release
Greenland Resources Inc. (TSX:MOLY, FSE:M0LY) (“Greenland Resources” or the “Company”) is pleased to announce the Company has signed a binding off-take agreement with SSAB, a Nordic and US-based steel producer headquartered in Sweden. The company is a leading producer on the global market for advanced high-strength steels providing solutions to the defence, automotive, infrastructure and energy industries. A stock exchange press release from SSAB can be found on their website at www.ssab.com This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401270749/en/ The off-take agreement provides an established price floor and price ceiling and will allow SSAB to secure high quality low carbon emission ferromolybdenum extracted in Greenland and refined in Belgium. SSAB will be able to ensure a stable and responsibly sourced long term secured primary molybdenum supply with high sustainability standards and low scope 1&2 emissions from a
VDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System1.4.2026 15:30:00 CEST | Press release
VDYNE, Inc. (“VDYNE” or “the Company”), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food & Drug Administration (FDA) has approved an investigational device exemption (IDE) for the company’s pivotal clinical trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system. The IDE approval enables initiation of a U.S. pivotal study at leading clinical centers to evaluate the safety and effectiveness of the VDYNE system in patients with severe tricuspid regurgitation (TR). “This is a defining milestone for VDYNE and an important step toward bringing a much-needed therapy to patients with severe tricuspid regurgitation,” said Mike Buck, Chief Executive Officer. “Our focus now is on disciplined clinical execution and partnering with leading investigators to generate high-quality data that advances the field and improves patient care.” Significant unmet clinical needs exist in the
NetJets Introduces State-of-the-Art, Exclusive-Use Terminal in Augusta, Georgia1.4.2026 15:05:00 CEST | Press release
New facility set to elevate the experience for customers during golf’s most celebrated event—and beyond NetJets, the global leader in private aviation, is well underway on its development of a new exclusive-use terminal at Augusta Regional Airport (AGS). This state-of-the-art facility represents a significant investment in the region and reinforces NetJets’ commitment to delivering unparalleled experiences for its customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330125414/en/ NetJets to open a new, exclusive-use terminal at Augusta Regional Airport (AGS). Guests arriving this April for golf’s most iconic championship will witness the construction in progress, including the finished ramp and foundational walls of what will soon become a full-service terminal. The private ramp, offering 432,000 square feet of space for aircraft parking, will be completed in time for the 2026 golf tournament. “Augusta is a key desti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom